Diabetic Peripheral Neuropathy Associated with Cardiovascular Risk Factors and Glucagon-Like Peptide-1 Concentrations Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus
Open Access
- 1 January 2022
- journal article
- research article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 35-44
Abstract
Purpose: This study was aimed at the prevalence, cardiovascular risk factors of diabetic peripheral neuropathy (DPN), and the relationship between DPN and fasting glucagon-like peptide-1 (fGLP-1) concentrations in newly diagnosed patients with type 2 diabetes mellitus (nT2D). Methods: A cross-sectional descriptive study was conducted from 2015 to 2020 with a population of 473 nT2D. Screening for DPN was based on the United Kingdom screening test. fGLP-1 was measured by enzyme-linked immunosorbent assay. Results: The prevalence of DPN was 26.6%, in which mild grade was 17.3%, moderate grade was 8.2% and severe grade was 1.1% in total. Age (OR = 1.73, 95% CI 1.12– 2.67, p = 0.012), smoking (OR = 1.64, 95% CI 1.03– 2.62, p = 0.037), poor control HbA1c (OR = 2.66, 95% CI 1.23– 5.76, p = 0.01), 24-h urinary albumin (24hUA) (OR = 2.49, 95% CI 1.26– 4.94, p = 0.007), and diabetic retinopathy (OR = 3.17, 95% CI 1.46– 6.89, p = 0.002) significantly increased the risk for DPN. In multivariate logistic regression analysis, hypertension (OR = 2.96, 95% CI 1.16– 7.55, p = 0.023), triglyceride (OR = 1.50, 95% CI 1.11– 2.03, p = 0.009), albumin (OR = 0.85, 95% CI 0.75– 0.95, p = 0.005), and fGLP-1 (OR = 0.79, 95% CI 0.67– 0.93, p = 0.005) correlated with DPN. The fGLP-1 concentrations were reduced significantly in DPN (p < 0.001). In particular, male patients with DPN had a significantly lower fGLP-1 levels than those without DPN (p < 0.001). Conclusion: The prevalence of DPN among nT2D was 26.6%. Age, smoking, hypertension, HbA1c control, triglyceride, albumin, 24hUA, diabetic retinopathy were the associated risk factors of DPN, and fGLP-1 was negatively correlated with DPN (OR = 0.79, 95% CI 0.67– 0.93, p = 0.005).Keywords
This publication has 57 references indexed in Scilit:
- Direct cardiovascular effects of glucagon like peptide-1Diabetology & Metabolic Syndrome, 2013
- Gut Peptide GLP-1 and Its Analogue, Exendin-4, Decrease Alcohol Intake and RewardPLOS ONE, 2013
- Incretin hormones as immunomodulators of atherosclerosisFrontiers in Endocrinology, 2012
- Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus in KoreaDiabetes & Metabolism Journal, 2012
- Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expressionBiochemical and Biophysical Research Communications, 2010
- Elevated Triglycerides Correlate With Progression of Diabetic NeuropathyDiabetes, 2009
- Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathyExperimental Neurology, 2007
- Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4The Journal of Pharmacology and Experimental Therapeutics, 2002
- Cigarette Smoking and Neuropathy in Diabetic PatientsDiabetes Care, 1990